نتایج جستجو برای: myeloablative conditioning

تعداد نتایج: 48131  

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010
Henk Lokhorst Hermann Einsele David Vesole Benedetto Bruno Jesus San Miguel Jose A Pérez-Simon Nicolaus Kröger Philippe Moreau Gosta Gahrton Cristina Gasparetto Sergio Giralt William Bensinger

PURPOSE To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. PATIENTS AND METHODS In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. RESULTS Although the introduction of reduced-intensity conditioning (RIC) has...

2016
Hee Young Ju Hyoung Jin Kang Che Ry Hong Ji Won Lee Hyery Kim Sang Hoon Song Kyung-Sang Yu In-Jin Jang June Dong Park Kyung Duk Park Hee Young Shin Joong-Gon Kim Hyo Seop Ahn

Chronic granulomatous disease (CGD) is a primary immunodeficiency disease caused by impaired phagocytic function. Hematopoietic stem cell transplantation (HSCT) is a definitive cure for CGD; however, the use of HSCT is limited because of associated problems, including transplantation-related mortality and engraftment failure. We report a case of a patient with CGD who underwent successful HSCT ...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2007
M Devetten J O Armitage

The use of hematopoietic cell transplantation has expanded and evolved substantially in the last decade. New stem cell sources and stem cell mobilizing agents have been introduced in clinical practice. The incidence of life-threatening complications following autologous stem cell transplant procedures has decreased dramatically. Understanding the immune mediated effect of allogeneic stem cell t...

Journal: :Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006
Paul J Martin Richard A Nash

This review addresses pitfalls of clinical trials to evaluate new approaches for prevention or treatment of graft-versus-host disease. Determination of end points poses a difficult challenge in the design of clinical trials, and examples from previous studies are used to illustrate some of the pitfalls. Also discussed is the need for a new conceptual approach for evaluation of graft-versus-host...

Journal: :Pediatric blood & cancer 2014
Johann K Hitzler Wensheng He John Doyle Mitchell Cairo Bruce M Camitta Ka Wah Chan Miguel A Diaz Perez Christopher Fraser Thomas G Gross John T Horan Alana A Kennedy-Nasser Carrie Kitko Joanne Kurtzberg Leslie Lehmann Tracey O'Brien Michael A Pulsipher Franklin O Smith Mei-Jie Zhang Mary Eapen Paul A Carpenter

We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was...

Journal: :European review for medical and pharmacological sciences 2010
I M Suslova D S Theodoropoulos N A M Cullen M K Tetarnikova A S Tetarnikov N A Kolchak

OBJECTIVES Successful treatment of severe, refractory Pemphigus vulgaris (PV) is reported. METHODS Reduced intensity, non-myeloablative conditioning was employed, followed by allogeneic hematopoietic stem cell transplantation (HSCT) from a fully matched sibling. RESULTS Treatment of refractory PV with myeloablation and subsequent allogenic HSCT has been previously reported, and sustained re...

Journal: :Pediatric blood & cancer 2013
Kayo Yamada Masahiro Yasui Osamu Kondo Maho Sato Akihisa Sawada Keisei Kawa Masami Inoue

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in children is one of the highest-risk ALL groups. Improved outcome in combination with imatinib has been reported. However, intensive chemotherapy or myeloablative conditioning followed by hematopoietic stem cell transplantation (HSCT) can be associated with significant adverse late effects. We report a case series of fiv...

Journal: :international journal of hematology-oncology and stem cell research 0
s keyhanian oncologist-hematologist, azad eslami university of medicine, tonekabon a ghavamzadeh oncologist-hematologist, hematology- oncology and bmt research center tehran university of medical sciences b bahar oncologist-hematologist, hematology- oncology and bmt research center tehran university of medical sciences k alimoghaddam oncologist-hematologist, hematology- oncology and bmt research center tehran university of medical sciences ar shamshiri student of epidemiology, hematology- oncology and bmt research center tehran university of medical sciences s gholibeikian data manager, hematology- oncology and bmt research center tehran university of medical sciences

background: myeloablative-allogeneic stem cell transplantation is a common way of treating various malignant and nonma-lignant diseases; but, it is associated with hazardous immediate and late complications. the majority of patients are not good candidates for high dose therapy because of old age, medical co-morbidities or previous heavy treatments. the donor stem cells can engraft in the recip...

2017
Olivier Hequet Valerie Mialou Francoise Audat Eric Wattel Valerie Chapel Damiela Revesz Jean-Piere Jouet Brigitte Fisseaux Mohamed Saoud Mauricette Michallet

Allogeneic hematopoietic stem cell transplantation can efficiently treat patients with severe hematological diseases. A human leukocyte antigen-compatible donor is required for performing transplantation. The occurrence of unexpected acute severe diseases in a donor can compromise the feasibility of allogeneic hematopoietic stem cell transplantation. However, when a severe health problem occurs...

Journal: :Hematology. American Society of Hematology. Education Program 2009
Monica S Thakar Stephen J Forman

A 35-year-old male with a FLT3(+) AML underwent allogeneic peripheral blood stem cell transplant using a myeloablative non-total body irradiation (TBI) conditioning regimen from his HLA-matched sibling donor. Following transplantation, he developed grade II acute graft-versus-host disease (GVHD) that resolved with increasing immunosuppression. The medications were subsequently discontinued, and...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید